Eton Pharmaceuticals, Inc. recently announced the completion of its acquisition of Galzin® (zinc acetate) from Teva ...
In a report released on December 3, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report). The company’s shares opened today at $12.28.
DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company ...
Make sure you're protected! Insure your ATV for as low as just $75/year.* Insure your 2001 E-TON for just $75/year.* Savings: We offer low rates and plenty of discounts. More riding freedom: You’re ...
Eton Pharmaceuticals Acquires Galzin® to Enhance Rare Disease Treatment Portfolio for Wilson Disease
Eton Pharmaceuticals, Inc. announced the acquisition of Galzin® (zinc acetate), an FDA-approved medication for the maintenance treatment of Wilson Disease, an ultra-rare metabolic condition ...
Adds an additional commercial and strategic rare disease product to Eton’s portfolio Galzin is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill.
DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results